Sharma, P. et al. Immune checkpoint therapy-current perspectives and future directions. Cell 186, 1652–1669 (2023).

Article  CAS  PubMed  Google Scholar 

Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok, J. D. et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 392, 11–22 (2025).

Article  CAS  PubMed  Google Scholar 

Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 378, 158–168 (2018).

Article  CAS  PubMed  Google Scholar 

Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).

Article  CAS  PubMed  Google Scholar 

Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16, 563–580 (2019).

Article  CAS  PubMed  Google Scholar 

Brahmer, J. R. et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J. Immunother. Cancer 9, e002435 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 1217–1238 (2022).

Article  CAS  PubMed  Google Scholar 

Schneider, B. J. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J. Clin. Oncol. 39, 4073–4126 (2021).

Article  CAS  PubMed  Google Scholar 

Thompson, J. A. et al. NCCN guidelines® insights: management of immunotherapy-related toxicities, version 2.2024. J. Natl Compr. Canc. Netw. 22, 582–592 (2024).

Article  PubMed  Google Scholar 

Pires da Silva, I. et al. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. Lancet Oncol. 22, 836–847 (2021).

Article  CAS  PubMed  Google Scholar 

Xing, P. et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. J. Immunother. Cancer 7, 341 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Som, A. et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J. Clin. Cases 7, 405–418 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Andrews, M. C. et al. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat. Med. 27, 1432–1441 (2021). A clinical study of patients with advanced melanoma and high-grade irAEs resulting from combined treatment of anti-CTLA-4 and anti-PD1, which shows increased B. intestinalis and serum IL-1β, findings that were recapitulated in mice colonized with B. intestinalis.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 28, 1368–1379 (2017). A prospective clinical study in patients with metastatic melanoma treated with anti-CTLA-4 that correlates the composition of the gut microbiota and circulating Tregcells with incidence of ICI colitis.

Article  CAS  PubMed  Google Scholar 

Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016). A prospective clinical study correlating the composition of the gut microbiome with incidence of ICI colitis in patients with metastatic melanoma treated with anti-CTLA-4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Moel, E. C. et al. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol. Res. 7, 6–11 (2019).

Article  PubMed  Google Scholar 

Mathias, K. et al. Association between rheumatic autoantibodies and immune-related adverse events. Oncologist 28, 440–448 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tahir, S. A. et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc. Natl Acad. Sci. USA 116, 22246–22251 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abu-Sbeih, H. et al. Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J. Clin. Oncol. 38, 576–583 (2020).

Article  CAS  PubMed  Google Scholar 

Johnson, D. B. et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2, 234–240 (2016).

Article  PubMed  Google Scholar 

Menzies, A. M. et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann. Oncol. 28, 368–376 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Berner, F. et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 5, 1043–1047 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Berner, F. et al. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. Sci. Immunol. 7, eabn9644 (2022).

Article  CAS  PubMed  Google Scholar 

Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749–1755 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra245 (2014).

Article  Google Scholar 

Kurimoto, C. et al. Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 111, 1468–1477 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lauwyck, J. et al. C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting. Melanoma Res. 31, 371–377 (2021).

Article  CAS  PubMed  Google Scholar 

Lim, S. Y. et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin. Cancer Res. 25, 1557–1563 (2019).

Article  CAS  PubMed  Google Scholar 

Onodera, R. et al. High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study. J. Thorac. Dis. 15, 4237–4247 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Tarhini, A. A. et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J. Immunother. Cancer 3, 39 (2015).

Article  PubMed  PubMed Central